These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30257195)

  • 1. Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection.
    Sou T; Kukavica-Ibrulj I; Soukarieh F; Halliday N; Levesque RC; Williams P; Stocks M; Cámara M; Friberg LE; Bergström CAS
    J Pharm Sci; 2019 Jan; 108(1):630-640. PubMed ID: 30257195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic-Pharmacodynamic Modeling for Evaluation of Treatments against Chronic
    Sou T; Kukavica-Ibrulj I; Levesque RC; Friberg LE; Bergström CAS
    Mol Pharm; 2020 May; 17(5):1458-1469. PubMed ID: 31951139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?
    Bos AC; van Holsbeke C; de Backer JW; van Westreenen M; Janssens HM; Vos WG; Tiddens HA
    PLoS One; 2015; 10(3):e0118454. PubMed ID: 25734630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.
    Torres BGS; Helfer VE; Bernardes PM; Macedo AJ; Nielsen EI; Friberg LE; Dalla Costa T
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.
    Alhariri M; Omri A
    Antimicrob Agents Chemother; 2013 Jan; 57(1):569-78. PubMed ID: 23147741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
    Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
    Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology.
    Costabile G; d'Angelo I; Rampioni G; Bondì R; Pompili B; Ascenzioni F; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Miro A; Quaglia F; Imperi F; Leoni L; Ungaro F
    Mol Pharm; 2015 Aug; 12(8):2604-17. PubMed ID: 25974285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia.
    Cigana C; Bernardini F; Facchini M; Alcalá-Franco B; Riva C; De Fino I; Rossi A; Ranucci S; Misson P; Chevalier E; Brodmann M; Schmitt M; Wach A; Dale GE; Obrecht D; Bragonzi A
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4991-5000. PubMed ID: 27297477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Activity of Berberine with Azithromycin against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung In Vitro and In Vivo.
    Li Y; Huang J; Li L; Liu L
    Cell Physiol Biochem; 2017; 42(4):1657-1669. PubMed ID: 28738346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E; Zhou S; Srikumar S; Duan W
    Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibiotic inhalation in cystic fibrosis. A review of the literature].
    Steinkamp G
    Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
    Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
    J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.